Not yet recruiting
An Exploratory Study of Single-Dose Neoadjuvant Nivolumab Without Surgical Delay in Patients With Resectable HCC
NCT07902258· Phase 2· National Taiwan University Hospital· Source
Contact: Dr.Ying-Chun Shen
Not yet recruiting
Hypofractionated Adjuvant Radiotherapy for Thymic Epithelial Tumors
NCT07693855· National Taiwan University Hospital· Source
Contact: Feng-Ming Hsu, M.D., Ph.D. (principal investigator)
Recruiting
ULTRA-high-risk Surveillance to Avoid Future Events: the ULTRA-SAFE Trial
NCT07378930· National Taiwan University Hospital· Source
Contact: Wei-Yuan Chang, MS
Recruiting
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
3D Virtual Resection for Predicting Lung Function in VATS
NCT07436598· National Taiwan University Hospital· Source
Contact: Chih-Hsiang Chang, MD
Recruiting
Ameliorated Pap Tests and Cervical Cancer Screening Participation
NCT06968871· National Taiwan University Hospital· Source
Contact: Ching-Ming Chiu, MD
Recruiting
Exploring Auger-Enhanced PSMA-Targeted Radioligand Therapy: A First-in-Taiwan Clinical Study of 161Tb-PSMA-I&T
NCT07621692· Phase 1· National Taiwan University Hospital· Source
Contact: Dr. Chuang
Not yet recruiting
Effect of Technology-Assisted Preoperative Home Exercise on Postoperative Handgrip Strength, Muscle Endurance, and Psychological Distress in Patients With Pulmonary Nodules Undergoing Video-Assisted Thoracoscopic Surgery
NCT07302217· National Taiwan University Hospital· Source
Contact: Li-Ping Chen
Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997· Phase 3· ArriVent BioPharma, Inc.· Source
Contact: Clinical Trials
Not yet recruiting
Ejaculatory Behavior and Seminal Vesicle Size During Radical Prostatectomy
NCT07243795· National Taiwan University Hospital· Source
Contact: Yen Ho, M.D.
Recruiting
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
Dissection of the Molecular and Immunological Interaction in Patients With HCC of Viral and Non-viral Etiologies
NCT05613621· National Health Research Institutes, Taiwan· Source
Recruiting
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
NCT06892548· Phase 1/2· BioNTech SE· Source
Recruiting
Nurse-Led Caregiver Support for Older Adults With Advanced Lung Cancer
NCT07708870· National Taiwan University Hospital· Source
Contact: Yeur-Hur Lai, PhD
Recruiting
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
NCT06801834· Phase 3· Gilead Sciences· Source
Recruiting
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
NCT06706076· Phase 1/2· BlossomHill Therapeutics· Source
Active, not recruiting
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824· Phase 3· Genmab· Source
Recruiting
Effects of Oral Administration of Antrodia Cinnamomea Products for Clinical Symptoms in Spinocerebellar Ataxia Patients
NCT06633003· ALPS Biotech CO. LTD· Source
Contact: Irene Tsai
Recruiting
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT06282575· Phase 3· Jazz Pharmaceuticals· Source
Contact: Clinical Trial Disclosure & Transparency
Active, not recruiting
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source
Active, not recruiting
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT06151574· Phase 3· Boehringer Ingelheim· Source
Active, not recruiting
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
NCT05696717· Phase 3· Theravance Biopharma· Source
Active, not recruiting
Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients
NCT05377034· Phase 2· National Cancer Centre, Singapore· Source
Active, not recruiting
A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients (TOPICS-THYROID)
NCT05541380· National Health Research Institutes, Taiwan· Source
Active, not recruiting
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
NCT05388669· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT05442060· Phase 2· OBI Pharma, Inc· Source
Contact: Anna Hu
Recruiting
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
NCT05429632· Phase 3· Priothera SAS· Source
Contact: Ko Bor-Sheng, MD
Recruiting
GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
NCT04864054· Phase 1/2· Eureka Therapeutics Inc.· Source
Contact: Guanlieng Chen
Recruiting
Development and Clinical Validation of Early-stage Lung Cancer Prognostic Kit
NCT05557474· Chung Shan Medical University· Source
Contact: Jin-Shing Chen, MD PhD
Recruiting
Primary Tumor Resection With EGFR TKI for Stage IV NSCLC
NCT05215548· Phase 2· National Taiwan University Hospital· Source
Contact: Jin-Shing Chen, M.D., Ph.D
Recruiting
Care Needs in Lung Cancer Patients Receiving Immunotherapy
NCT06433206· National Taiwan University Hospital· Source
Contact: Meng Ping Hsiao, Master